^
Association details:
| Biomarker: | KRAS G61H + KRAS G12A |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer
Excerpt:
Baseline mutations in genes: BRAF, KRAS, NRAS. Mutations detected in tumor tissue during routine work‐up and in cfDNA prior to start of cetuximab monotherapy...While almost all patients with additional KRAS or BRAF mutations were resistant to therapy, we also had one patient with clinical benefit who nevertheless had a polyclonal KRAS mutation (p.G61H and p.G12A) in ctDNA...While almost all patients with additional KRAS or BRAF mutations were resistant to therapy, we also had one patient with clinical benefit who nevertheless had a polyclonal KRAS mutation (p.G61H and p.G12A) in ctDNA...
DOI:
10.1002/1878-0261.12550
